NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Pliant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On Februar ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Pliant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Februa ...

Pliant Therapeutics, Inc. (PLRX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investo ...

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025. The following abstracts are posted on ATS 2025’s online itinerary planner for registered users. Pliant was selected for a featured oral presentation as part of the ATS 2025 Mini Symposiums prog ...

Pliant Therapeutics Inc. ( PLRX ) is a cash-rich biotech company that has been working on the discovery and development of therapeutics for the treatment of fibrotic disease. It recently had a substantial setback with its lead drug candidateI am interested in small capitalized companies with a high optionality to the upside compared to the relative downside risk. I am grounded in a value based approach but will also explore special and short situations. I am a trained CPA and continue to practice in industr ...

Shares of Pliant Therapeutics (PLRX) have plunged 88.5% in the past three months following recent setbacks in the clinical development program of its lead product candidate, bexotegrast (PLN-74809), for treating idiopathic pulmonary fibrosis (IPF). Bexotegrast is an oral, small-molecule, dual selective inhibitor of αvß6 and αvß1 integrins.IPF is the most prevalent and severe type of progressive pulmonary fibrosis, impacting around 150,000 patients in the United States and more than three million worldwide.P ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Fa ...

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizu ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their OptionsIf you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]NEW YORK, March 13, 2025 /PRNewswire/ -- Faruqi & ...

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of ...